Press release
Tuberculosis Pipeline Insight 2023 (Updated) | Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, and others.
Tuberculosis Pipeline
In the Tuberculosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Tuberculosis clinical trials studies, Tuberculosis NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Tuberculosis Pipeline Report
• DelveInsight's Tuberculosis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Tuberculosis treatment.
• The leading Tuberculosis companies include Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd, TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.
• Promising Tuberculosis pipeline therapies include VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607, and others.
• The Tuberculosis companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The Tuberculosis pipeline therapies under development are focused on novel approaches to treat/improve Tuberculosis.
Request a sample and discover the recent breakthroughs happening in the Tuberculosis Pipeline landscape @ Tuberculosis Pipeline Outlook- https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Tuberculosis Overview
Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.
Recent Developmental Activities in the Tuberculosis Treatment Landscape
• In January 2022, GlaxoSmithKline's GSK-3036656 saw its Phase Transition Success Rate (PTSR) climb seven points to 55% after its Phase II pulmonary tuberculosis trial was completed.
• In March 2022, Bharat Biotech announced a partnership with Biofabri, a Spanish biopharmaceutical company, to develop, manufacture and market a new tuberculosis vaccine 'MTBVAC'. The partnership guarantee the supply of TB vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa.
• In April 2022, Moderna and the nonprofit scientific research organization IAVI entered into a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats, including HIV/AIDS, tuberculosis (TB), and antimicrobial-resistant enteric infections, and COVID-19.
For further information, refer to the detailed Tuberculosis Drugs Launch, Tuberculosis Developmental Activities, and Tuberculosis News, click here for Tuberculosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Tuberculosis Emerging Drugs Profile
• Telacebec (Q203): Qurient Co
Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.
• VPM1002: Serum Institute of India
VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.
Tuberculosis Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies for Tuberculosis. The companies which have their Tuberculosis drug candidates in the mid to advanced stage, i.e. Phase III include, Qurient Co
Find out more about the Tuberculosis Pipeline Segmentation, Therapeutics Assessment, and Tuberculosis Emerging Drugs @ Tuberculosis Treatment Landscape- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Tuberculosis Pipeline Report
• Coverage- Global
• Tuberculosis Companies- Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd, TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.
• Tuberculosis Pipeline Therapies- VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607, and others
• Tuberculosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Tuberculosis Pipeline Companies and Therapies, click here @ Tuberculosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Tuberculosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Telacebec (Q203): Qurient Co
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. WX-081: Shanghai Jiatan Pharmatech
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. OPC-167832: Otsuka Pharmaceutical
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Tuberculosis Key Companies
17. Tuberculosis Key Products
18. Tuberculosis- Unmet Needs
19. Tuberculosis- Market Drivers and Barriers
20. Tuberculosis- Future Perspectives and Conclusion
21. Tuberculosis Analyst Views
22. Tuberculosis Key Companies
23. Appendix
Got Queries? Find out the related information on Tuberculosis Mergers and acquisitions, Tuberculosis Licensing Activities @ Tuberculosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash Bhardwaj
info@delveinsight.com
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tuberculosis Pipeline Insight 2023 (Updated) | Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, and others. here
News-ID: 3176598 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Tuberculosis
Revolutionizing the Fight Against Tuberculosis: Global Anti-Tuberculosis Therape …
The global Anti-Tuberculosis (TB) Therapeutics Market is on the cusp of a transformative era, driven by urgent medical need, groundbreaking scientific advances, and expanding public-private partnerships. With an estimated 10 million new TB cases reported worldwide in 2022 and 1.4 million deaths, tuberculosis remains a leading infectious disease killer, commanding critical attention from healthcare providers, governments, and pharmaceutical innovators alike. As the world rallies to eliminate this centuries-old scourge, the…
Latent Tuberculosis Infection Detection Market
Latent Tuberculosis Infection Detection Market worth $2.37 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Latent Tuberculosis Infection Detection Market - (By Brand (QFT-Plus), By Test Type (Tuberculin Skin Test (TST), Interferon Gamma Release Assay (IGRA)), By Application, By End-use), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research…
Tuberculosis (TB) Diagnostics Market - Detect, Diagnose, Defeat: Innovating Solu …
Newark, New Castle, USA - new report, titled Tuberculosis (TB) Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Tuberculosis (TB) Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Tuberculosis (TB) Diagnostics market. The report offers an overview of…
Conquering Tuberculosis: Exploring the Innovations in Mycobacterium Tuberculosis …
The global mycobacterium tuberculosis treatment market was valued at US$ 1.97 Bn in 2021 and is expected to increase at a CAGR of 1.2% over the forecast period 2022-2032.
Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB), which mostly affects the lungs. Tuberculosis is a major public health crisis concern; however, it can be cured and prevented. Adults are most often affected by tuberculosis during their most productive years. Over…
World Tuberculosis Day - Tuberculosis, the invisible pandemic
Tuberculosis is a disease that, every year, kills as many as COVID-19 does.
March 24, World Tuberculosis Day, marks the anniversary of a momentous occasion - the discovery of the bacterium which causes tuberculosis in 1882. More than a hundred years after its discovery, tuberculosis is still a global health crisis. It is the leading cause of death from a single infectious disease agent, killing close to as many people per…
Ocular Tuberculosis Therapeutics Market To Expand On Account Of Rising Tuberculo …
Research Nester released a report titled “Ocular Tuberculosis Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global ocular tuberculosis therapeutics market in terms of market segmentation by treatment, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Ocular tuberculosis is a type…
